<DOC>
	<DOCNO>NCT00580242</DOCNO>
	<brief_summary>This study propose use bortezomib cohort 3-6 patient dose 0.7 , 1 , 1.3 mg/m2 day 1 , 4 , 8 , 11 determine MTD combination lenalidomide 10 mg day , 21 day 28 day treatment cycle patient myelodysplastic syndrome .</brief_summary>
	<brief_title>A Phase 1 Dose Escalating Trial Bortezomib Combination With Lenalidomide Patients With Myelodysplasia</brief_title>
	<detailed_description>Currently , curative therapy myelodysplasia except allogeneic stem cell transplantation . Both lenalidomide bortezomib activity single agent patient myelodysplasia . This study propose use bortezomib cohort 3-6 patient dose 0.7 , 1 , 1.3 mg/m2 day 1 , 4 , 8 , 11 determine MTD combination withlenalidomide 10 mg day , 21 day 28 day treatment cycle . The planned bortezomib dos evaluate previous Phase I clinical study similar patient population safe well tolerate twice-weekly schedule administration . Lenalidomide show efficacy myelodysplasia . The combination lenalidomide bortezomib use patient multiple myeloma .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients may untreated previously treat . Age &gt; 18 year Able adhere study schedule protocol requirement Unequivocal clinicopathologic diagnosis myelodysplastic syndrome , non 5q deletion . Patients may prior chemotherapy radiotherapy another malignancy myelodysplasia long complete least 4 week ( 6 week nitrosureas ) prior initiation therapy . ECOG performance status 02 ( Appendix 10.3 ) Life expectancy great 3 month Total bilirubin ≤ 2.0 mg/dl , ALT AST ≤ 3 X upper limit normal ( ULN ) , creatinine &lt; 2.0 mg/dl within 28 day prior enrollment . Patients must give voluntary write informed consent HIPAA authorization performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . Absolute neutrophil count &gt; 0.5 x 10 ( 9 ) /l Platelet count &gt; 30 x 10 ( 9 ) /l Prior treatment 5azacytidine encourage , require . Patients may prior treatment MDS , include single agent lenalidomide bortezomib . Females childbearing potential ( FCBP ) must negative serum urine pregnancy test sensitivity least 50mIU/ml within 1014 day prior within 24 hour prescribe lenalidomide must commit abstinence heterosexual intercourse begin TWO acceptable method birth control , least 4 week start take lenalidomide . FCBP must agree ongoing pregnancy test . Men must agree father child agree use latex condom sexual contact female child bear potential even successful vasectomy . All study participant must register mandatory RevAssist Program® , willing able comply requirement RevAssist® . Ejection fraction &lt; 40 % Patients myocardial infarction within 6 month enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen document investigator medically relevant . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject sign consent form . Any condition , include laboratory abnormality , opinion investigator place subject unacceptable risk he/she participate study confounds ability interpret data study . Patients major surgery within 28 day prior trial enrollment . Patients ≥ Grade 2 peripheral neuropathy active herpes infection Patients uncontrolled intercurrent illness include , limited , ongoing active infection , cirrhosis , chronic obstructive restrictive pulmonary disease , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrythmia . Patients secondary MDS require concurrent therapy primary cancer diagnosis . The development erythema nodosum characterize desquamate rash take thalidomide similar drug . Patient hypersensitivity bortezomib , boron mannitol . Female subject pregnant breastfeeding . . Lactating female must agree breast feed take lenalidomide . Patient receive investigational drug within 28 day enrollment . Known hypersensitivity thalidomide lenalidomide Concurrent use anticancer agent treatment . Known positive HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Myelodysplasia</keyword>
</DOC>